Alliance Wealth Advisors LLC UT Has $2.44 Million Position in Abbott Laboratories $ABT

Alliance Wealth Advisors LLC UT lowered its stake in Abbott Laboratories (NYSE:ABT) by 30.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,225 shares of the healthcare product maker’s stock after selling 8,086 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Abbott Laboratories were worth $2,441,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Lansforsakringar Fondforvaltning AB publ lifted its stake in Abbott Laboratories by 2.2% in the third quarter. Lansforsakringar Fondforvaltning AB publ now owns 546,192 shares of the healthcare product maker’s stock valued at $73,157,000 after buying an additional 11,822 shares during the period. ANTIPODES PARTNERS Ltd raised its position in shares of Abbott Laboratories by 11.7% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 828 shares of the healthcare product maker’s stock valued at $111,000 after acquiring an additional 87 shares during the period. Siligmueller & Norvid Wealth Advisors LLC bought a new position in Abbott Laboratories during the 3rd quarter worth approximately $1,545,000. Asahi Life Asset Management CO. LTD. acquired a new position in Abbott Laboratories during the third quarter valued at approximately $431,000. Finally, Coyle Financial Counsel LLC increased its stake in Abbott Laboratories by 6.3% in the third quarter. Coyle Financial Counsel LLC now owns 6,380 shares of the healthcare product maker’s stock valued at $855,000 after purchasing an additional 379 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, February 4th. The stock was purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 0.0%

NYSE ABT opened at $112.21 on Friday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock’s 50 day moving average price is $118.46 and its two-hundred day moving average price is $125.84. The stock has a market capitalization of $195.11 billion, a price-to-earnings ratio of 30.16, a PEG ratio of 1.79 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were given a $0.63 dividend. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Exact Sciences stockholders approved Abbott’s acquisition proposal (preliminary results showed >99% of votes cast and ~67% of outstanding shares represented), clearing a key shareholder hurdle and advancing Abbott’s expansion into cancer screening/diagnostics — a strategic deal that should broaden revenue mix and long-term growth prospects. Exact Sciences Stockholders Approve Acquisition by Abbott
• Positive Sentiment: Abbott’s board declared its 409th consecutive quarterly dividend at $0.63/share, reinforcing a reliable income profile that supports shareholder confidence and may attract income-oriented investors. Abbott declares 409th consecutive quarterly dividend
• Positive Sentiment: Abbott reported positive clinical results for its Amulet 360 Left Atrial Appendage (LAA) occluder presented at the AF Symposium — a favorable outcome for the company’s structural-heart/device pipeline that could support future market adoption and revenue growth in electrophysiology/cardiology. Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
• Neutral Sentiment: Abbott’s board approved governance changes to streamline the board (smaller board size). This is a modest corporate-governance move that could slightly improve oversight/efficiency but is unlikely to drive material near-term earnings changes. Abbott Laboratories Streamlines Governance With Smaller Board
• Neutral Sentiment: Media comparisons (BSX vs ABT) highlight Abbott’s valuation appeal, CGM momentum and strategic deals as advantages vs. Boston Scientific — useful context for investors but not a direct corporate action. BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
• Negative Sentiment: BTIG cut its price target for ABT to $140, which may temper near-term analyst-driven upside and investor enthusiasm despite the company’s strategic wins; analyst revisions can influence sentiment and trading volume. BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABT. Argus reduced their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Barclays lowered their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. Evercore dropped their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Leerink Partners decreased their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.